DDInter1936 DDInter1763
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Vinblastine {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Vinblastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Vinblastine {u} (Compound) upregulates {v} (Gene) LRP10
LRP10 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Vinblastine {u} (Compound) downregulates {v} (Gene) RAD51AP1
RAD51AP1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Vinblastine {u} (Compound) downregulates {v} (Gene) PIK3R4
PIK3R4 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Vinblastine {u} (Compound) binds {v} (Gene) TUBG1
TUBG1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Vinblastine {u} (Compound) upregulates {v} (Gene) JMJD6
JMJD6 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Vinblastine {u} (Compound) causes {v} (Side Effect) Pharyngitis
Pharyngitis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Vinblastine (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)
Vinblastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Vinblastine (Compound) upregulates LRP10 (Gene) and LRP10 (Gene) is upregulated by Temsirolimus (Compound)
Vinblastine (Compound) downregulates RAD51AP1 (Gene) and RAD51AP1 (Gene) is upregulated by Temsirolimus (Compound)
Vinblastine (Compound) downregulates PIK3R4 (Gene) and PIK3R4 (Gene) is downregulated by Temsirolimus (Compound)
Vinblastine (Compound) binds TUBG1 (Gene) and TUBG1 (Gene) is downregulated by Temsirolimus (Compound)
Vinblastine (Compound) upregulates JMJD6 (Gene) and JMJD6 (Gene) is downregulated by Temsirolimus (Compound)
Vinblastine (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Temsirolimus (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)